Lilly says retatrutide data package is complete, targets early 2027 FDA filing

Eli Lilly said on Aug. 5, 2026 that the clinical data package for retatrutide is complete and that it plans to submit the drug to the US Food and Drug Administration in the first quarter of 2027 for obesity, obstructive sleep apnea and knee osteoarthritis pain ^[2]. Retatrutide is an investigational triple agonist. It is not approved for any use, and it is not the same drug as semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) ^[1].

The filing plan rests on Phase 3 results. Lilly's second-quarter release refers to positive data from three additional Phase 3 retatrutide trials in obesity ^[2]. A monthly industry log describes two trials, TRIUMPH-2 and TRIUMPH-3, whose topline results were reported on July 23, 2026 ^[1]. In TRIUMPH-3, adults with severe obesity and established cardiovascular disease lost up to 22.6% of body weight at 80 weeks. In TRIUMPH-2, participants with type 2 diabetes lost up to 20.8% at the same timepoint ^[1]. The two accounts differ on how many trials the package covers, and that difference is not explained in either.

The regulatory path is unsettled. Lilly has said it intends to file a Biologics License Application rather than a New Drug Application, a choice that remains subject to unresolved litigation with the FDA ^[1]. The agency had determined that retatrutide is neither a protein nor a biological product; a district court vacated that designation but returned the wider question to the agency, and Lilly has appealed ^[1]. The distinction matters because the two application types carry different exclusivity periods, 12 years against five ^[1]. The Seventh Circuit is scheduled to hear oral arguments in Lilly's appeal on Sept. 24, 2026 ^[1].

Retatrutide sits inside a crowded period for Lilly's weight-loss business. The company reported second-quarter 2026 revenue of $23.0 billion, up 48% from a year earlier, with Mounjaro revenue up 91% to $9.9 billion and US Zepbound revenue up 46% to $4.9 billion ^[2]. Lilly also submitted orforglipron, its oral GLP-1, for type 2 diabetes in the US during the quarter; the FDA approved that medicine for obesity in April 2026 ^[1]. Separately, Lilly has brought six US lawsuits against sellers of unapproved retatrutide ^[1].

Why it matters for patients

Retatrutide cannot be prescribed in the US today, and a filing in early 2027 would still be followed by an FDA review of undisclosed length before any approval decision. That has not been reported ^[1]. Because the drug is unapproved, any retatrutide sold online or through clinics is not FDA-reviewed product, and Lilly is pursuing sellers in court ^[1].

The three conditions Lilly plans to file for go beyond weight loss. Obstructive sleep apnea and knee osteoarthritis pain are separate indications, and each would require its own review before it could appear on a label. Whether the FDA accepts all three at once has not been disclosed ^[1].

How the biologic-versus-drug question is resolved affects something patients feel indirectly: how long Lilly's protection lasts before competing versions can enter the market. Twelve years instead of five is a seven-year difference in when lower-cost copies could plausibly appear, though no source describes what those products would be or what they would cost ^[1].

What happens next

The Seventh Circuit hears oral arguments in Lilly's appeal on Sept. 24, 2026 ^[1]. Lilly has guided to a first-quarter 2027 submission ^[1][2]. Further readouts from the TRIUMPH program are expected before the end of 2026 ^[1]. The timing of any FDA decision on retatrutide, and the conditions it might cover, have not been disclosed ^[1].